PubRank

Arun J Sanyal

Author PubWeight™ 245.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 29.57
2 The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012 11.03
3 Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007 9.44
4 The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012 5.47
5 Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003 4.69
6 Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008 4.07
7 Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008 3.68
8 A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007 3.65
9 The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013 3.51
10 The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009 3.48
11 Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004 3.45
12 Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011 3.37
13 Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2007 3.06
14 Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2011 2.97
15 The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007 2.94
16 Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010 2.86
17 Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013 2.82
18 Sepsis-induced cholestasis. Hepatology 2007 2.80
19 Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013 2.70
20 Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009 2.42
21 Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009 2.40
22 The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011 2.37
23 An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol 2010 2.18
24 Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2008 2.17
25 Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2010 2.16
26 Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology 2009 2.16
27 Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008 2.10
28 Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2012 2.01
29 Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007 1.99
30 Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012 1.97
31 Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol 2009 1.93
32 The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology 2013 1.92
33 Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007 1.90
34 Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014 1.89
35 Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol 2007 1.87
36 Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012 1.86
37 MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl 2007 1.86
38 Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2011 1.85
39 Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010 1.77
40 Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004 1.76
41 Effect of hyponatraemia on outcomes following orthotopic liver transplantation. Liver Int 2009 1.76
42 Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012 1.70
43 The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012 1.61
44 Portal hypertensive bleeding. Gastroenterol Clin North Am 2003 1.60
45 Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009 1.59
46 Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2010 1.58
47 Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010 1.55
48 Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 2010 1.52
49 Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010 1.52
50 Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013 1.51
51 Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006 1.50
52 Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2009 1.48
53 Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 2011 1.44
54 Recurrent variceal bleeding despite endoscopic and medical therapy. Gastroenterology 2004 1.39
55 Ascites: diagnosis and management. Med Clin North Am 2009 1.37
56 Drug-induced steatohepatitis. Clin Liver Dis 2003 1.36
57 A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004 1.33
58 Endoplasmic reticulum stress and the unfolded protein response. Clin Liver Dis 2009 1.28
59 Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 2008 1.24
60 Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004 1.22
61 Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009 1.21
62 Portal hypertension and variceal hemorrhage. Med Clin North Am 2008 1.19
63 Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am J Gastroenterol 2010 1.17
64 The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol 2002 1.16
65 The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2002 1.16
66 HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology 2009 1.15
67 Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004 1.15
68 Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2009 1.13
69 A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2011 1.12
70 Clinical aspects of fatty liver disease. Semin Liver Dis 2004 1.11
71 Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013 1.10
72 Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol 2008 1.10
73 Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005 1.09
74 Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response? Am J Gastroenterol 2004 1.08
75 Evaluation and management of non-alcoholic steatohepatitis. J Hepatol 2004 1.07
76 The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol 2009 1.06
77 Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Semin Liver Dis 2008 1.05
78 A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int 2008 1.01
79 Association between puberty and features of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012 1.01
80 Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol 2003 1.00
81 A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007 0.99
82 Novel treatment modalities for nonalcoholic steatohepatitis. Trends Endocrinol Metab 2010 0.96
83 Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012 0.96
84 Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH). PLoS One 2012 0.96
85 Scavenger receptor A restrains T-cell activation and protects against concanavalin A-induced hepatic injury. Hepatology 2013 0.94
86 Lipotoxicity in NASH. J Hepatol 2011 0.94
87 The histologic spectrum of nonalcoholic fatty liver disease. Clin Liver Dis 2004 0.94
88 Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol 2006 0.93
89 Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int 2012 0.92
90 Driving simulation can improve insight into impaired driving skills in cirrhosis. Dig Dis Sci 2011 0.92
91 Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J Hepatol 2013 0.92
92 Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008 0.92
93 Role of microRNAs in non-alcoholic steatohepatitis. Curr Pharm Des 2010 0.92
94 Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 2012 0.91
95 Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem Biophys Res Commun 2012 0.90
96 Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol 2010 0.90
97 Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study. Liver Transpl 2012 0.90
98 Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004 0.90
99 Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival. Liver Int 2013 0.89
100 Grading portal gastropathy: validation of a gastropathy scoring system. Am J Gastroenterol 2003 0.88
101 Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes. Liver Transpl 2009 0.87
102 A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008 0.87
103 Multiple classes of environmental chemicals are associated with liver disease: NHANES 2003-2004. Int J Hyg Environ Health 2013 0.87
104 Acute variceal hemorrhage. Gastrointest Endosc Clin N Am 2007 0.86
105 Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. J Hepatol 2012 0.85
106 Use of desirability functions to evaluate health status in patients with cirrhosis. J Hepatol 2010 0.85
107 Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis. Metab Brain Dis 2014 0.85
108 Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection. Clin Gastroenterol Hepatol 2004 0.85
109 Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis. Clin Gastroenterol Hepatol 2011 0.85
110 The role of CCAAT enhancer-binding protein homologous protein in human immunodeficiency virus protease-inhibitor-induced hepatic lipotoxicity in mice. Hepatology 2013 0.84
111 Pregnancy and liver disease. Gastroenterol Clin North Am 2003 0.84
112 Herpes simplex virus colitis in a patient with Crohn's disease and hepatitis B and d cirrhosis. Gastroenterol Hepatol (N Y) 2010 0.84
113 Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis 2008 0.83
114 Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 2007 0.82
115 Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways. J Pharmacol Exp Ther 2010 0.82
116 Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. PLoS One 2013 0.82
117 Sepsis and cholestasis. Clin Liver Dis 2008 0.82
118 Pathophysiology guided treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2012 0.82
119 Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002 0.82
120 The molecular pathogenesis of cholestasis in sepsis. Front Biosci (Elite Ed) 2013 0.82
121 The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. Am J Gastroenterol 2005 0.81
122 Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 2007 0.81
123 Role of obesity, insulin resistance, and steatosis in hepatitis C virus infection. Clin Liver Dis 2006 0.81
124 Physiologic concentrations of leptin increase collagen production by non-immortalized human hepatic stellate cells. Metabolism 2006 0.81
125 Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C. J Clin Gastroenterol 2011 0.80
126 5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model. Mol Pharmacol 2012 0.79
127 Recurrent flares of pancreatitis predict development of exocrine insufficiency in chronic pancreatitis. Clin Gastroenterol Hepatol 2007 0.79
128 Insulin resistance and tissue repair: a "fato-logical" phenomenon. Gastroenterology 2003 0.79
129 Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. J Gastroenterol 2011 0.78
130 The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr 2003 0.78
131 Drug-induced steatohepatitis. Clin Liver Dis 2013 0.78
132 Nonalcoholic fatty liver disease. MedGenMed 2003 0.78
133 Evaluation and management of non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2004 0.77
134 Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol 2010 0.76
135 Invasive and non-invasive techniques for detecting portal hypertension and predicting variceal bleeding in cirrhosis: a review. Ann Med 2013 0.76
136 Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology 2005 0.76
137 Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (β-Cell) Function. Dig Dis Sci 2015 0.76
138 Hepatorenal syndrome. Curr Treat Options Gastroenterol 2005 0.76
139 Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int 2014 0.76
140 A Lipidomic Readout of Disease Progression in A Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease. Trans Am Clin Climatol Assoc 2015 0.75
141 Sirtuins and the hepatic regulation of energy homeostasis. Hepatology 2009 0.75
142 Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study. J Clin Gastroenterol 2016 0.75
143 Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology 2011 0.75
144 Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2017 0.75
145 Coagulation and hemostasis in liver disease: controversies and advances. Preface. Clin Liver Dis 2009 0.75
146 Management of ascites in cirrhosis. Clin Liver Dis 2005 0.75
147 Coagulation disorders and bleeding in liver disease: future directions. Clin Liver Dis 2009 0.75
148 Long Term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis Related Cirrhosis. Transplantation 2017 0.75
149 Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology 2016 0.75
150 Brain Integrity Changes underlying Cognitive and Functional Recovery Postliver Transplant Continue to Evolve Over 1 Year. Transplantation 2017 0.75
151 Corrigendum: Treatment of NASH: What Helps Beyond Weight Loss? Am J Gastroenterol 2017 0.75